BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics reported a significant increase in net loss for Q1 2026, reaching $42.1 million, nearly double the $22.1 million loss in Q1 2025. This was primarily driven by a substantial rise in research and development expenses, which increased by 92.8% to $39.8 million. The company's cash and cash equivalents decreased to $52.7 million from $373.7 million at year-end 2025, though total liquidity including marketable securities remained strong at $388.9 million. The company completed a de-SPAC transaction in August 2025, raising $260.9 million in PIPE financing.

BridgeBio Oncology Therapeutics reported its first quarter 2026 financial results, alongside significant clinical progress across its three RAS-pathway inhibitor programs. The company announced encouraging preliminary safety and efficacy data for BBO-8520, BBO-11818 (including a partial response in pancreatic cancer), and BBO-10203. BBOT also extended its cash runway into 2028 and made key management appointments, including Pedro J. Beltran as CEO.

BridgeBio Oncology Therapeutics reported encouraging preliminary safety and efficacy data across all three of its RAS-pathway inhibitor programs, BBO-8520, BBO-11818, and BBO-10203, with clinical readouts expected in the second half of 2026. The company also announced Q1 2026 financial results, including a net loss of $42.1 million, and confirmed a cash runway into 2028 with $388.9 million in cash. Additionally, key management changes were announced, including a new CEO and COO.

BridgeBio Oncology Therapeutics, Inc. announced it awarded inducement grants on May 10, 2026, to one individual hired in March 2026. The grants consist of non-qualified stock options to purchase 32,675 shares of common stock at an exercise price of $7.66 per share. These awards were made under the company's 2025 Inducement Plan as a material inducement for employment and will vest over time, subject to continued service.

BridgeBio Oncology Therapeutics, Inc. (BBOT) announced its 2026 Annual Meeting of Stockholders will be held virtually on June 16, 2026. Stockholders will vote on the election of two Class I directors and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for 2026. Michelle Doig will not stand for re-election, and the board size will be reduced from nine to eight directors.

BridgeBio Oncology Therapeutics, Inc. announced the appointment of Pedro Beltran, Ph.D., as its new President and Chief Executive Officer, effective April 20, 2026. Dr. Beltran also joins the Board of Directors as a Class III director. He succeeds Eli Wallace, Ph.D., who resigned from his CEO and director positions but is expected to continue as an advisor to the company. Dr. Wallace's resignation was not due to any disagreement with the company's policies.

BridgeBio Oncology Therapeutics, Inc. (BBOT) announced significant leadership changes, appointing Pedro J. Beltran, PhD, as Chief Executive Officer and Idan Elmelech as Chief Operating Officer, effective April 20, 2026. Neil Kumar, PhD, a co-founder, was named Executive Chairman, while former CEO Eli Wallace, PhD, transitioned to Senior Adviser. These appointments are intended to guide BBOT through its next development phase as its clinical assets advance into expansions and combinations for RAS-driven cancers, aiming for accelerated program development and strategic execution.

BridgeBio Oncology Therapeutics (BBOT) presented new preclinical data for BBO-10203, a first-in-class covalent small molecule RAS:PI3K A breaker, at the AACR Annual Meeting 2026. The data showed BBO-10203 physically disrupts the interaction between RAS and PI3K A, leading to signaling inhibition and tumor regressions without observed hyperglycemia. The drug also demonstrated strong in vivo combination effects with HER2 inhibitors in HER2AMP models, and its mechanism is independent of RAS or PI3K A mutational status, potentially broadening its patient population. BBO-10203 is currently in a Phase 1 trial, with updated clinical data anticipated in the second half of 2026.

BridgeBio Oncology Therapeutics (BBOT) announced that the FDA granted Fast Track designation to its pan-KRAS inhibitor, BBO-11818, for advanced KRAS-mutant pancreatic ductal adenocarcinoma. This designation aims to accelerate the development and review process for the drug, which previously showed a confirmed partial response in pancreatic cancer in preliminary data released in January 2026. The company expects updated Phase 1 clinical data in the second half of 2026.

BridgeBio Oncology Therapeutics, Inc. (BBOT) announced it awarded inducement grants of non-qualified stock options for 32,675 shares to a new employee hired in March 2026. The options, with an exercise price of $8.40 per share, were granted under BBOT's 2025 Inducement Plan as a material inducement for employment. Vesting occurs 1/4 on the first anniversary of the start date, followed by 36 equal monthly installments.